Lung cancer in never smokers: from early detection to prevention.
2/5 보강
TL;DR
Why LCINS demands unique clinical and research paradigms to address its biological complexity is discussed, and low-dose computed tomography screening shows promise in high-risk subgroups.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: lung cancer who have never smoked, symptoms are nonspecific and often dismissed due to these patients not fitting a high-risk profile (e
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Novel prevention approaches, from interleukin (IL)-1β inhibition to cancer vaccines, are under investigation. This opinion article discusses why LCINS demands unique clinical and research paradigms to address its biological complexity.
OpenAlex 토픽 ·
Lung Cancer Treatments and Mutations
Lung Cancer Diagnosis and Treatment
Cancer Immunotherapy and Biomarkers
Why LCINS demands unique clinical and research paradigms to address its biological complexity is discussed, and low-dose computed tomography screening shows promise in high-risk subgroups.
APA
Deborah R. Caswell, Crispin T. Hiley, et al. (2026). Lung cancer in never smokers: from early detection to prevention.. Trends in cancer, 12(4), 310-319. https://doi.org/10.1016/j.trecan.2025.12.009
MLA
Deborah R. Caswell, et al.. "Lung cancer in never smokers: from early detection to prevention.." Trends in cancer, vol. 12, no. 4, 2026, pp. 310-319.
PMID
41680064 ↗
Abstract 한글 요약
Lung cancer in never smokers (LCINS) is a growing global health challenge. Unlike smoking-related lung cancer, LCINS is characterized by distinct epidemiological patterns and unique molecular pathogenesis and, consequently, requires different clinical management approaches. Unfortunately, for patients with lung cancer who have never smoked, symptoms are nonspecific and often dismissed due to these patients not fitting a high-risk profile (e.g., smoker), underscoring the need for improved detection and interception. Emerging risk factors, including germline variants, clonal hematopoiesis, and environmental exposures, offer new avenues for risk stratification and preventive strategies. While low-dose computed tomography screening shows promise in high-risk subgroups, challenges remain in optimizing cost-effectiveness. Novel prevention approaches, from interleukin (IL)-1β inhibition to cancer vaccines, are under investigation. This opinion article discusses why LCINS demands unique clinical and research paradigms to address its biological complexity.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.